Allergic Rhinitis Treatment Market is Segmented By Drug Type (Antihistamines, Intranasal Corticosteroids, Immunotherapies, Decongestants, Other), By Disease Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Allergic Rhinitis Treatment Market is Expected to reach at a CAGR of 6.9% during the forecast period (2024-2031).
Allergic rhinitis is a diagnosis that refers to symptoms that affect the nose. These symptoms appear when one inhales something they are allergic to, such as dust, animal dander, or pollen.
Allergic Rhinitis Treatment Market
|
Metrics |
Details |
|
Market CAGR |
6.9 |
|
Segments Covered |
By Drug Type, By Disease Type, By Distribution Channel, By Vehicle and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Allergic Rhinitis Treatment Market Dynamics
The factors influencing the growth of the global allergic rhinitis treatment market are the increasing demand for allergic rhinitis treatment and the increasing prevalence of allergic rhinitis.
The increasing demand for allergic rhinitis treatment is expected to drive the market growth
An allergen is a harmless substance that causes an allergic reaction. Allergic rhinitis, also known as hay fever, is an allergic reaction to a specific allergen. The most common allergen in seasonal allergic rhinitis is pollen. These are allergy symptoms that occur as the season's change. According to the American Academy of Allergy, Asthma, and Immunology, nearly 8% of adults in the United States have allergic rhinitis of some kind (AAAAI). Allergic rhinitis affects between 10% and 30% of the global population. The rising healthcare spending is expected to increase demand for better quality and faster diagnostic methods to treat perennial allergic rhinitis. Respiratory disease imposes a significant burden on society regarding disability and premature mortality and direct healthcare costs, drugs prescribed, and indirect costs associated with lost production. Perennial allergic rhinitis is frequently treated in conjunction with allergic asthma. This condition is also having an effect on the global market for allergic rhinitis treatment. Another factor driving the growth of the perennial allergic rhinitis market is increasing patient awareness of perennial allergic rhinitis treatment worldwide. Several government organizations have launched awareness campaigns to raise awareness about allergic rhinitis. Allergy UK, for instance, is the operational name of the British Allergy Foundation, which observes allergy awareness week from April 25 to May 1.
Side effects associated with allergic rhinitis treatment is expected to hamper the market growth
Antihistamine nasal sprays are generally well tolerated. Bitter taste in the mouth, headache, drowsiness, dry mouth and nose, pyrexia, cough, epistaxis, sneezing, rhinalgia, upper respiratory infection, vomiting, nasal burning, irritation, eye redness, and oropharyngeal pain are all common side effects. Decongestants can be effective treatments for allergic rhinitis with congestion. Many people, especially in the spring and winter months, use or misuse excessive doses of decongestant agents to relieve allergic congestive symptoms without a doctor's prescription. Nasal decongestants have a high risk of abuse. Long-term use of decongestant nasal spray (and, in rare cases, oral decongestants) can result in rhinitis medicamentosa or rebound nasal congestion (RM). Hence, all these factors are expected to hamper market growth.
COVID-19 Impact Analysis
Allergic patients with asthma, rhinitis, and conjunctivitis experienced acute relapses during the COVID-19 emergency, both because of the massive spring exposure to allergens and other triggering factors such as internal and external pollutants and as a result of the abrupt interruption of current treatment for fear that the same drugs could facilitate SARS infection. Hence, due to COVID-19, the demand for allergic rhinitis treatment is expected to grow.
Allergic Rhinitis Treatment Market Segment Analysis
Based on drug type, the antihistamines segment is expected to dominate the market growth
Antihistamines alleviate allergic rhinitis symptoms by inhibiting the action of histamine, a chemical released by the body when it feels it is under attack from an allergen. Antihistamines that target the histamine H1 receptor can help patients with allergic rhinitis improve and maintain their quality of life. A classification based on their detailed characteristics is required for the more effective and safer second-generation drugs recommended by various guidelines. Oral antihistamines, in general, have been shown to relieve histamine-mediated symptoms associated with allergic rhinitis effectively. Second-generation antihistamines are useful for many patients with mild symptoms who require as-needed treatment because their onset of action is typically within 15 to 30 minutes. They are considered safe for children over the age of two. This segment is expected to dominate the market growth in the forecast period due to the increasing launches of antihistamines to treat allergic rhinitis. For instance, June 17th, 2021, the U.S FDA approved a nasal antihistamine for non-prescription use today, using a process known as a partial prescription to non-prescription switch. The FDA has approved Astepro (azelastine hydrochloride nasal spray, 0.15 percent) for seasonal and perennial allergic rhinitis, also known as allergies, in adults and children six years of age and older.
Allergic Rhinitis Treatment Market Geographical Analysis
North America region is expected to hold the largest market share in the global allergic rhinitis treatment market
The increasing incidence of allergic rhinitis and increasing research & development in this region is expected to drive the market growth.
Allergic rhinitis affects productivity and quality of life in children and adults and is estimated to affect 15 to 30% of patients in the United States. Furthermore, the increasing FDA approvals are expected to drive this region's market growth. For instance, on January 14th, 2022, the US Food and Drug Administration (FDA) approved a prescription nasal spray for seasonal allergic rhinitis. Ryaltris (mometasone furoate monohydrate) is approved for adults and pediatric patients aged 12 and up. Hence, the market in this region is expected to grow in the forecast period.
Allergic Rhinitis Treatment Market Competitive Landscape
The global allergic rhinitis treatment market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Merck & Co., Boehringer Ingelheim, GlaxoSmithKline PLC, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, Mylan NV, Sun Pharmaceuticals, Stallergenes Greer
Glenmark Pharmaceuticals Limited
Overview: Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with operations in over 80 countries and a presence in generics, specialty, and over-the-counter (OTC) businesses. Glenmark's primary therapeutic areas of interest are respiratory, dermatology, and oncology. The company was founded in 1977.
Product Portfolio: Ryaltris is a nasal spray that comes in a metered-dose manual spray unit and contains an isotonic aqueous white homogenous suspension. It has a pH of roughly 3.7. Ryaltris is approved to treat allergic rhinitis and rhinoconjunctivitis in patients 12 years of age and older.
Key Developments: On January 14th, 2022, Glenmark Specialty S.A. received FDA approval for Ryaltris, a nasal spray fixed-dose prescription drug used to treat seasonal allergic rhinitis.
